Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
Joanna Szydzik, Dan E. Lind, Badrul Arefin, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Targeting DNA damage response pathways in cancer
Florian J. Groelly, Matthew Fawkes, Rebecca A. Dagg, et al.
Nature reviews. Cancer (2022) Vol. 23, Iss. 2, pp. 78-94
Closed Access | Times Cited: 461
Key Proteins of Replication Stress Response and Cell Cycle Control as Cancer Therapy Targets
Alvina I. Khamidullina, Yaroslav E. Abramenko, Alexandra V. Bruter, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 1263-1263
Open Access | Times Cited: 21
Disassembly of the TRIM56-ATR complex promotes cytoDNA/cGAS/STING axis–dependent intervertebral disc inflammatory degeneration
Wei-Feng Zhang, Gaocai Li, Xingyu Zhou, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 6
Open Access | Times Cited: 16
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition
Marcus Borenäs, Ganesh Umapathy, Dan E. Lind, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 121, Iss. 1
Open Access | Times Cited: 13
Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing Nrf2 activity
Qingqing Ruan, Chunmei Wen, Guihua Jin, et al.
Phytomedicine (2023) Vol. 118, pp. 154990-154990
Closed Access | Times Cited: 11
DNA damage response deficiency enhances neuroblastoma progression and sensitivity to combination PARP and ATR inhibition
Madeline N. Hayes, Sarah Cohen‐Gogo, Lynn Kee, et al.
Cell Reports (2025) Vol. 44, Iss. 4, pp. 115537-115537
Open Access
IGF1R Contributes to Cell Proliferation in ALK-Mutated Neuroblastoma with Preference for Activating the PI3K-AKT Signaling Pathway
Jikui Guan, Marcus Borenäs, Junfeng Xiong, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4252-4252
Open Access | Times Cited: 9
Anaplastic Lymphoma Kinase signaling stabilizes SLC3A2 expression via MARCH11 to promote neuroblastoma cell growth
Wei‐Yun Lai, Tzu‐Po Chuang, Marcus Borenäs, et al.
Cell Death and Differentiation (2024)
Open Access | Times Cited: 3
Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN
Jonatan L. Gabre, Peter Merseburger, A. Claeys, et al.
NAR Cancer (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 2
Chemo-Phosphoproteomic Profiling with ATR Inhibitors Berzosertib and Gartisertib Uncovers New Biomarkers and DNA Damage Response Regulators
Rathan S Jadav, Florian Weiland, Sylvie M. Noordermeer, et al.
Molecular & Cellular Proteomics (2024) Vol. 23, Iss. 8, pp. 100802-100802
Open Access | Times Cited: 2
Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR)
Liwei Wang, Songwei Jiang, Yinghui Yuan, et al.
Molecules (2022) Vol. 27, Iss. 8, pp. 2491-2491
Open Access | Times Cited: 9
Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Fabian F. Pusch, Heathcliff Dorado García, Robin Xu, et al.
Molecular Cancer Therapeutics (2023) Vol. 23, Iss. 4, pp. 507-519
Open Access | Times Cited: 4
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC
Abdulmalik A. Bokhari, Wei‐Yun Lai, Anh T. Le, et al.
Lung Cancer (2022) Vol. 171, pp. 103-114
Open Access | Times Cited: 7
Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model
Arman Romiani, Daniella Pettersson, Nishte Rassol, et al.
(2024)
Open Access | Times Cited: 1
Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma
Ahmed Abu‐Zaid, Jie Fang, Hongjian Jin, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 3, pp. 101468-101468
Open Access | Times Cited: 1
Inhibition of the ATR-DNAPKcs-RB axis drives G1/S-phase transition and sensitizes triple-negative breast cancer (TNBC) to DNA holliday junctions
Yuemiao Hu, Xuecun Liu, Lei Hu, et al.
Biochemical Pharmacology (2024) Vol. 225, pp. 116310-116310
Closed Access | Times Cited: 1
DNA repair and replicative stress addiction in neuroblastoma
Kaat Durinck, Meredith S. Irwin
EJC Paediatric Oncology (2024) Vol. 4, pp. 100177-100177
Closed Access | Times Cited: 1
METTL3/MYCN cooperation drives neural crest differentiation and provides therapeutic vulnerability in neuroblastoma
Ketan Thombare, Roshan Vaid, Perla Pucci, et al.
The EMBO Journal (2024)
Closed Access | Times Cited: 1
Pentacyclic triterpene-amino acid derivatives induced apoptosis and autophagy in tumor cells, affected the JNK and PI3K/AKT/mTOR pathway
Liqiong Zhang, Li Sun, Yuqing Zhou, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 94, pp. 117478-117478
Closed Access | Times Cited: 3
Therapeutic inhibition of ATR in differentiated thyroid cancer
Shu‐Fu Lin, Yi-Yin Lee, Ming‐Hsien Wu, et al.
Endocrine Related Cancer (2023) Vol. 30, Iss. 12
Open Access | Times Cited: 3
Promising Molecular Targets and Novel Therapeutic Approaches in Neuroblastoma
Xu Yang, Jixia Li, Jigang Yang
Current Pharmacology Reports (2022) Vol. 9, Iss. 1, pp. 43-58
Open Access | Times Cited: 4
Advances in the treatment of solid tumors in children and adolescents
Jing Tian, Jiayu Wang, Sidan Li
Cancer Innovation (2023) Vol. 2, Iss. 2, pp. 131-139
Open Access | Times Cited: 2
Targeting ATR in Cancer Medicine
Carolina Salguero, Christian Valladolid, Helen M.R. Robinson, et al.
Cancer treatment and research (2023), pp. 239-283
Closed Access | Times Cited: 2
The suppression of ATR/Chk1 pathway by Elimusertib ATR inhibitor in triple negative breast cancer cells.
Ayten Haciefendi, Gamze Güney Eskiler
PubMed (2023) Vol. 15, Iss. 7, pp. 4902-4911
Closed Access | Times Cited: 1
ALK signalling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition
Marcus Borenäs, Ganesh Umapathy, Dan E. Lind, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top